Statement from Recursion regarding REC-994 Trial
Recursion’s message to our patients regarding the discontinuation of the REC-994 trial: We have difficult news to share today. Recursion has made the decision to discontinue the SYCAMORE trial of…
Recursion’s message to our patients regarding the discontinuation of the REC-994 trial: We have difficult news to share today. Recursion has made the decision to discontinue the SYCAMORE trial of…
The Ann & Robert H. Lurie Children’s Hospital of Chicago has been recognized as a designated Clinical Center by the Alliance to Cure Cavernous Malformation for the treatment of cavernous…
We are thrilled to announce that the Phase 2 safety trial of Recursion’s REC-994 medicine, being developed specifically for symptomatic CCM, has fully enrolled 60 patients ahead of schedule. Our…
On this Rare Disease Day, we are honored to announce the National Organization for Rare Disorders (NORD) has awarded the Alliance to Cure Cavernous Malformation this year’s prestigious Abbey S….
Thomas Jefferson University Hospitals in Philadelphia, Pennsylvania has been recognized as a designated Clinical Center by the Alliance to Cure Cavernous Malformation for the treatment of cavernous malformations. A cavernous…